KUALA LUMPUR: CCM Duopharma Biotech Bhd’s net profit increased 80 per cent to RM11.41 million in the third quarter ended September 30, 2017, from RM6.34 million a year ago.
This was attributed to lower production cost and other operational costs despite marginal decrease in revenue.
In an exchange filing today, CCM Duopharma’s revenue rose 43.69 per cent to RM115.38 million from RM80.30 million in the same quarter last year.
This was due to increased demand from public health sector via tenders and supply of traded speciality products.
CCM Duopharma said the pharmaceutical industry is expected to remain stable for the current year ending December 31 2017 (FY17).
“We expect to achieve satisfactory results in FY17, premised on healthy demand from all business segments and introduction of new products into the market.”